Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Debt to Equity (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Debt to Equity over the past 9 years, most recently at $0.05 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.05 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $0.05 (changed N/A YoY), and the annual figure for FY2025 was $0.05, changed.
  • Debt to Equity for Q4 2025 was $0.05 at Viridian Therapeutics, Inc.\DE, up from $0.04 in the prior quarter.
  • Over the last five years, Debt to Equity for VRDN hit a ceiling of $0.05 in Q4 2025 and a floor of $0.03 in Q3 2024.
  • Median Debt to Equity over the past 3 years was $0.04 (2025), compared with a mean of $0.04.
  • Peak annual rise in Debt to Equity hit 43.18% in 2025, while the deepest fall reached 4.44% in 2025.
  • Viridian Therapeutics, Inc.\DE's Debt to Equity stood at $0.05 in 2023, then crashed by 36.54% to $0.03 in 2024, then soared by 63.47% to $0.05 in 2025.
  • The last three reported values for Debt to Equity were $0.05 (Q4 2025), $0.04 (Q3 2025), and $0.04 (Q2 2025) per Business Quant data.